ContraVir Pharmaceuticals to Present Three Posters at the 53rd Annual International Liver CongressTM
Share
Print
April 03, 2018 06:00 ET | Source: ContraVir Pharmaceuticals Inc
EDISON, NJ, April 03, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), confirmed today That three abstracts have been accepted for poster presentations by the Scientific Program Committee of The International Liver CongressTM 2018 to be held in Paris, France from April 11-15, 2018.
Robert Foster, Pharm D., Ph.D, Chief Scientific Officer of ContraVir Pharmaceuticals, will present all three posters and will be available for interviews onsite at the ILC Press Office.
Abstract #1: Pharmacokinetic-Pharmacodynamic Modeling of Tenofovir Exalidex in HBV Subjects
Abstract Number: 3094
Date and Time: April 13, 2018 from 9:00 AM to 5:00 PM
Session: Viral Hepatitis B/D: Therapy
Abstract #2: Assessing the in vitro anti-HBV Activity of Combinations including CRV431, TXL, and Prototype Capsid Assembly Modulators
Abstract Number: 2615
Date and Time: April 14, 2018 from 9:00 AM to 5:00 PM
Session: Viral Hepatitis A, B, C, D, E: Virology
Abstract Number: 2624
Date and Time: April 14, 2018 from 9:00 AM to 5:00 PM
Session: Viral Hepatitis A, B, C, D, E: Virology
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL TM, designed to deliver high intrahepatic concentrations of TFV while minimizing off-target effects caused by high levels of circulating TFV (bone and kidney), most recently completed a Phase 2a trial. CRV431, the other anti-HBV compound, is a next-generation Cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg). For more information visit www.contravir .com
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations [email protected]; (732) 902-4028 作者: StephenW 时间: 2018-4-4 10:48
ContraVir制药公司将在第53届国际肝脏年会上发布三张海报
分享
打印
2018年4月3日06:00 ET |来源：ContraVir制药公司